

Vincent Thibault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/725951/publications.pdf>

Version: 2024-02-01

144
papers

9,043
citations

61984

43
h-index

40979

93
g-index

147
all docs

147
docs citations

147
times ranked

7452
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Influence of preanalytical parameters on influenza and respiratory syncytial virus molecular detection. <i>Journal of Clinical Virology</i> , 2022, 147, 105063. | 3.1 | 0 |
| 2 | Efficient and Quality-Optimized Metagenomic Pipeline Designed for Taxonomic Classification in Routine Microbiological Clinical Tests. <i>Microorganisms</i> , 2022, 10, 711. | 3.6 | 9 |
| 3 | Acute hepatitis B virus infection despite vaccination in a patient treated by infliximab: a case report. <i>BMC Gastroenterology</i> , 2022, 22, . | 2.0 | 7 |
| 4 | Respiratory Influenza viral load as a marker of poor prognosis in patients with severe symptoms. <i>Journal of Clinical Virology</i> , 2021, 136, 104761. | 3.1 | 11 |
| 5 | Performances of NeuMoDx [®] , a random-access system for hepatitis B virus DNA and hepatitis C virus RNA quantification. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1693.e9-1693.e15. | 6.0 | 3 |
| 6 | European multicenter evaluation of Xpert [®] Xpress SARS-CoV-2/Flu/RSV test. <i>Journal of Medical Virology</i> , 2021, 93, 5798-5804. | 5.0 | 21 |
| 7 | Editorial: HBV cure—the quest for biomarkers to predict off-treatment sustained response. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 552-554. | 3.7 | 3 |
| 8 | When a viral eruption hides another one: intrafamilial outbreak of parvovirus B19 and measles virus co-infections: case report. <i>BMC Infectious Diseases</i> , 2020, 20, 496. | 2.9 | 2 |
| 9 | A Highly Prevalent Polymorphism in the Core Region Impairs Quantification of Hepatitis B Virus (HBV) by the cobas TaqMan HBV Assay. <i>Journal of Clinical Microbiology</i> , 2020, 58, . | 3.9 | 4 |
| 10 | Combined use of dried blood spot and rapid molecular systems: A robust solution to monitor hepatitis B virus infection with potential for resource-limited countries. <i>Journal of Virological Methods</i> , 2020, 283, 113908. | 2.1 | 5 |
| 11 | The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection. <i>Journal of Clinical Virology</i> , 2020, 129, 104507. | 3.1 | 9 |
| 12 | Short-term survival of acute respiratory distress syndrome patients due to influenza virus infection alone: a cohort study. <i>ERJ Open Research</i> , 2020, 6, 00587-2020. | 2.6 | 1 |
| 13 | Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1276-1283. | 2.0 | 1 |
| 14 | High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 678-681. | 2.5 | 6 |
| 15 | LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320. | 3.7 | 15 |
| 16 | Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 145-147. | 8.1 | 3 |
| 17 | Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 302-309. | 1.6 | 2 |
| 18 | Performance comparison of new Veris and Xpert random access HIV-1 RNA quantification assays. <i>Virology Journal</i> , 2018, 15, 156. | 3.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127. | 3.7 | 28 |
| 20 | Contribution of quantitative viral markers to document hepatitis B virus compartmentalization in cerebrospinal fluid during hepatitis B with neuropathies. <i>Journal of NeuroVirology</i> , 2018, 24, 769-772. | 2.1 | 10 |
| 21 | Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease (NAFLD), compared to chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD). <i>Journal of Hepatology</i> , 2018, 68, S99-S100. | 3.7 | 2 |
| 22 | Serum CXCL10, CXCL11, CXCL12, and CXCL14 chemokine patterns in patients with acute liver injury. <i>Cytokine</i> , 2018, 111, 500-504. | 3.2 | 16 |
| 23 | Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples. <i>Journal of Clinical Virology</i> , 2017, 89, 14-21. | 3.1 | 18 |
| 24 | Chronic hepatitis E in HIV/HBV coinfecting patient. <i>Aids</i> , 2017, 31, 1346-1348. | 2.2 | 22 |
| 25 | Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436. | 2.5 | 13 |
| 26 | Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0174651. | 2.5 | 1 |
| 27 | Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1750-1756. | 2.8 | 15 |
| 28 | Too Often Forgotten: Passive Transfer of Antibodies: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 709-710. | 5.8 | 9 |
| 29 | Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782. | 0.9 | 136 |
| 30 | Hepatitis E infection in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1367-1371. | 1.6 | 2 |
| 31 | Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms. <i>Journal of Viral Hepatitis</i> , 2015, 22, 718-726. | 2.0 | 11 |
| 32 | Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. <i>Journal of Clinical Virology</i> , 2015, 69, 203-209. | 3.1 | 6 |
| 33 | Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2195-2202. | 3.9 | 21 |
| 34 | Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification. <i>Journal of Clinical Virology</i> , 2015, 62, 32-37. | 3.1 | 20 |
| 35 | PegIFN±/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. <i>Journal of Hepatology</i> , 2015, 62, 24-30. | 3.7 | 86 |
| 36 | Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647. | 3.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 60, 706-714. | 3.7 | 101 |
| 38 | Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 61, 994-1003. | 3.7 | 42 |
| 39 | Could Droplet Digital PCR Be Used Instead of Real-Time PCR for Quantitative Detection of the Hepatitis B Virus Genome in Plasma?. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3497-3498. | 3.9 | 18 |
| 40 | Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. <i>Virology Journal</i> , 2013, 10, 87. | 3.4 | 8 |
| 41 | Adjustment of antiretroviral regimen may lead to HBV reactivation even in patients with past HBV infection serological profile. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 987-989. | 1.7 | 6 |
| 42 | Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. <i>Journal of Clinical Virology</i> , 2013, 58, 408-414. | 3.1 | 7 |
| 43 | Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013, 58, 385-390. | 3.1 | 10 |
| 44 | Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683. | 3.7 | 134 |
| 45 | Sequencing Assays for Failed Genotyping with the Versant Hepatitis C Virus Genotype Assay (LiPA), Version 2.0. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2815-2821. | 3.9 | 35 |
| 46 | Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1428-1433. | 3.9 | 3 |
| 47 | Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune-Mediated Inflammatory Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1504-1514. | 3.4 | 43 |
| 48 | Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1356-1359. | 2.2 | 13 |
| 49 | Molecular Epidemiology and Clinical Characteristics of Hepatitis B Identified through the French Mandatory Notification System. <i>PLoS ONE</i> , 2013, 8, e75267. | 2.5 | 10 |
| 50 | Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon- α 2a in a patient with HIV/HCV co-infection. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 937-938. | 1.7 | 3 |
| 51 | Lack of TGF- β 2 production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. <i>Journal of Hepatology</i> , 2012, 56, 1259-1268. | 3.7 | 9 |
| 52 | Fatal fulminant primary hepatitis B virus infections with G1896A precore viral mutants in southeastern France. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, e1-e8. | 1.5 | 11 |
| 53 | Performance of the DiaSorin LIAISON [®] anti-HBs II for the detection of hepatitis B surface antibodies: Comparison with the Abbott Architect anti-HBs assay. <i>Journal of Clinical Virology</i> , 2011, 50, 297-302. | 3.1 | 18 |
| 54 | HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 204-213. | 1.5 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. <i>Antiviral Therapy</i> , 2011, 16, 199-205. | 1.0 | 21 |
| 56 | Genotype 4 hepatitis C virus: Beware of false-negative RNA detection. <i>Hepatology</i> , 2011, 53, 1066-1067. | 7.3 | 9 |
| 57 | Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011, 11, 496-503. | 2.3 | 14 |
| 58 | Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077. | 27.0 | 683 |
| 59 | Hepatitis C Transmission in Injection Drug Users: Could Swabs Be the Main Culprit?. <i>Journal of Infectious Diseases</i> , 2011, 204, 1839-1842. | 4.0 | 26 |
| 60 | Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantification Limits. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1113-1115. | 3.9 | 10 |
| 61 | Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?. <i>Aids</i> , 2010, 24, 1078-1079. | 2.2 | 27 |
| 62 | Molecular analysis of HBV genotypes and subgenotypes in the Central-East region of Tunisia. <i>Virology Journal</i> , 2010, 7, 302. | 3.4 | 24 |
| 63 | Assessment of adrenal function in cirrhotic patients: Salivary cortisol should be preferred. <i>Journal of Hepatology</i> , 2010, 52, 839-845. | 3.7 | 102 |
| 64 | HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. <i>Fertility and Sterility</i> , 2010, 93, 1020-1023. | 1.0 | 32 |
| 65 | Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. <i>Aids</i> , 2009, 23, 2079-2089. | 2.2 | 63 |
| 66 | Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. <i>Journal of Virological Methods</i> , 2009, 159, 265-270. | 2.1 | 9 |
| 67 | Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035. | 5.0 | 56 |
| 68 | Low Levels of Hepatitis C Virus (HCV) Neutralizing Antibodies in Patients Coinfected with HCV and Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2008, 198, 332-335. | 4.0 | 8 |
| 69 | Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men. <i>Aids</i> , 2008, 22, 658-661. | 2.2 | 21 |
| 70 | An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load. <i>PLoS ONE</i> , 2008, 3, e2573. | 2.5 | 64 |
| 71 | Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. <i>Antiviral Therapy</i> , 2008, 13, 895-900. | 1.0 | 8 |
| 72 | Efficacy and Safety of Adefovir Dipivoxil plus Pegylated Interferon- α 2a for the Treatment of Lamivudine-Resistant Hepatitis B virus Infection in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2008, 13, 895-900. | 1.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3948-3953. | 3.9 | 40 |
| 74 | Multicenter Trials Need To Use the Same Assay for Hepatitis C Virus Viral Load Determination. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3788-3790. | 3.9 | 15 |
| 75 | A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. <i>Virology Journal</i> , 2007, 4, 35. | 3.4 | 19 |
| 76 | Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 847-858. | 3.7 | 43 |
| 77 | Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. <i>Journal of Hepatology</i> , 2006, 44, 62-67. | 3.7 | 89 |
| 78 | Where does adefovir stand amongst newly developed antivirals: from pharmacology to virology. <i>Future Virology</i> , 2006, 1, 553-565. | 1.8 | 2 |
| 79 | Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. <i>Comparative Hepatology</i> , 2006, 5, 1. | 0.9 | 30 |
| 80 | A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. <i>Journal of Viral Hepatitis</i> , 2006, 13, 182-189. | 2.0 | 14 |
| 81 | Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. <i>Journal of Viral Hepatitis</i> , 2006, 13, 329-335. | 2.0 | 51 |
| 82 | Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. <i>Arthritis and Rheumatism</i> , 2006, 54, 3696-3706. | 6.7 | 227 |
| 83 | Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. <i>Aids</i> , 2006, 20, 1157-1161. | 2.2 | 95 |
| 84 | Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of Determinant Variants. <i>Journal of Virology</i> , 2006, 80, 2968-2975. | 3.4 | 153 |
| 85 | Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2250-2253. | 3.9 | 36 |
| 86 | Expertise of Laboratories in Viral Load Quantification, Genotyping, and Precore Mutant Determination for Hepatitis B Virus in a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3600-3607. | 3.9 | 34 |
| 87 | Changing Electrolyte and Acido-Basic Profile in HIV-Infected Patients in the HAART Era. <i>Nephron Physiology</i> , 2006, 103, p131-p138. | 1.2 | 21 |
| 88 | Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?. <i>American Journal of Gastroenterology</i> , 2006, 101, 1260-1267. | 0.4 | 124 |
| 89 | Unique NS5b Hepatitis C Virus Gene Sequence Consensus Database Is Essential for Standardization of Genotype Determinations in Multicenter Epidemiological Studies. <i>Journal of Clinical Microbiology</i> , 2006, 44, 614-616. | 3.9 | 22 |
| 90 | A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2006, 52, 1887-1896. | 3.2 | 210 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. <i>Antiviral Therapy</i> , 2006, 11, 1103-6. | 1.0 | 7 |
| 92 | Comparison of Hepatitis C Virus NS5b and 5'â€² Noncoding Gene Sequencing Methods in a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2005, 43, 733-739. | 3.9 | 81 |
| 93 | Longitudinal Assessment of Histology Surrogate Markers (FibroTest-ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1970-1980. | 0.4 | 128 |
| 94 | Hepatitis B virus genotypes and extrahepatic manifestations. <i>Journal of Hepatology</i> , 2005, 43, 764-770. | 3.7 | 104 |
| 95 | Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 323-33. | 2.3 | 102 |
| 96 | Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2004, 50, 1344-1355. | 3.2 | 286 |
| 97 | Expertise of French Laboratories in Detection, Genotyping, and Quantification of Hepatitis C Virus RNA in Serum. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2027-2030. | 3.9 | 15 |
| 98 | Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, . | 2.3 | 42 |
| 99 | Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIVâ€™hepatitis C virus co-infection. <i>Aids</i> , 2004, 18, 123-127. | 2.2 | 13 |
| 100 | Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 2004, 50, 3668-3678. | 6.7 | 104 |
| 101 | TaqMan amplification system with an internal positive control for HCV RNA quantitation. <i>Journal of Clinical Virology</i> , 2004, 31, 227-234. | 3.1 | 75 |
| 102 | Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1367-1373. | 1.6 | 27 |
| 103 | Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. <i>Aids</i> , 2004, 18, 75-79. | 2.2 | 45 |
| 104 | <i>In Vitro</i> Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir. <i>Antiviral Therapy</i> , 2004, 9, 353-363. | 1.0 | 101 |
| 105 | Noninvasive prediction of fibrosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2003, 37, 1220-1221. | 7.3 | 91 |
| 106 | The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2003, 10, 103-110. | 2.0 | 13 |
| 107 | Potential Exposure to Hepatitis C Virus through Accidental Blood Contact in Interventional Radiology. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, 173-179. | 0.5 | 18 |
| 108 | Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2003, 124, A763. | 1.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Comparison of Viral replication fitness of wild-type and lamivudine-resistant HBV in patients. <i>Gastroenterology</i> , 2003, 124, A709. | 1.3 | 0 |
| 110 | Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 222-230. | 3.7 | 322 |
| 111 | Tenofovir Disoproxil Fumarate in Patients with HIV and Lamivudine-Resistant Hepatitis B Virus. <i>New England Journal of Medicine</i> , 2003, 348, 177-178. | 27.0 | 157 |
| 112 | Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure. <i>Gut</i> , 2003, 52, 614-a-614. | 12.1 | 15 |
| 113 | Multicenter Quality Control for the Detection of Hepatitis C Virus RNA in Seminal Plasma Specimens. <i>Journal of Clinical Microbiology</i> , 2003, 41, 789-793. | 3.9 | 27 |
| 114 | Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. <i>Aids</i> , 2003, 17, 721-725. | 2.2 | 176 |
| 115 | Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1586-1588. | 3.2 | 66 |
| 116 | Hepatitis C Virus Infection in Long-term Nonprogressor HIV-1-Infected Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 204-206. | 2.1 | 3 |
| 117 | Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. <i>Aids</i> , 2002, 16, 713-717. | 2.2 | 44 |
| 118 | Human Leukocyte Antigen Class II Alleles May Contribute to the Severity of Hepatitis C Virus-Related Liver Disease. <i>Journal of Infectious Diseases</i> , 2002, 186, 106-109. | 4.0 | 44 |
| 119 | Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients. <i>Journal of Hepatology</i> , 2002, 36, 18. | 3.7 | 1 |
| 120 | Quantitative HBV-DNA testing: are we ready for international units?. <i>Journal of Hepatology</i> , 2002, 36, 132. | 3.7 | 0 |
| 121 | Long term use of adefovir in HIV-HBV coinfecting patients is not associated with emergence of specific HBV polymerase mutations. <i>Journal of Hepatology</i> , 2002, 36, 132-133. | 3.7 | 0 |
| 122 | Use of Inno-Lipa HBV-DR to assess the sensitivity of lamivudine-resistant HBV mutants to adefovir. <i>Journal of Hepatology</i> , 2002, 36, 133. | 3.7 | 0 |
| 123 | Interferon- γ and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 3317-3326. | 6.7 | 171 |
| 124 | Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: Results from a randomized control trial. <i>Hepatology</i> , 2002, 35, 238-239. | 7.3 | 9 |
| 125 | Primary infection with a lamivudine-resistant hepatitis B virus. <i>Aids</i> , 2002, 16, 131-133. | 2.2 | 74 |
| 126 | Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. <i>Lancet</i> , The, 2001, 358, 718-723. | 13.7 | 320 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2001, 44, 2118-2124. | 6.7 | 78 |
| 128 | Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfecting patients: Impact of protease inhibitor therapy. <i>Hepatology</i> , 2001, 34, 283-287. | 7.3 | 378 |
| 129 | Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. <i>Aids</i> , 2001, 15, 2463-2464. | 2.2 | 9 |
| 130 | Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. <i>Journal of Viral Hepatitis</i> , 2000, 7, 15-22. | 2.0 | 82 |
| 131 | Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay. <i>Journal of Virological Methods</i> , 2000, 85, 117-124. | 2.1 | 12 |
| 132 | Comparative Analysis of Translation Efficiencies of Hepatitis C Virus 5' Untranslated Regions among Intraindividual Quasispecies Present in Chronic Infection: Opposite Behaviors Depending on Cell Type. <i>Journal of Virology</i> , 2000, 74, 10827-10833. | 3.4 | 68 |
| 133 | Liver fibrosis in overweight patients. <i>Gastroenterology</i> , 2000, 118, 1117-1123. | 1.3 | 861 |
| 134 | Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. <i>Journal of Hepatology</i> , 2000, 33, 121-127. | 3.7 | 30 |
| 135 | Impact of hepatitis B and C virus on kidney transplantation outcome. <i>Hepatology</i> , 1999, 29, 257-263. | 7.3 | 521 |
| 136 | Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. <i>Hepatology</i> , 1999, 30, 1302-1306. | 7.3 | 414 |
| 137 | Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. <i>Journal of Hepatology</i> , 1999, 31, 598-603. | 3.7 | 60 |
| 138 | Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients Coinfected with HBV and Human Immunodeficiency Virus. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3013-3016. | 3.9 | 69 |
| 139 | Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. <i>Hepatology</i> , 1998, 27, 868-872. | 7.3 | 286 |
| 140 | Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 422-424. | 0.9 | 17 |
| 141 | Antibodies to rat soluble IL-6 receptor stimulate B9 hybridoma cell proliferation. <i>FEBS Letters</i> , 1997, 408, 182-186. | 2.8 | 4 |
| 142 | Construction and Characterization of a Replication-Deficient Adenovirus Expressing Rat-Soluble Interleukin-6 Receptor. <i>Molecular Medicine</i> , 1997, 3, 519-529. | 4.4 | 3 |
| 143 | More on HBe Ag-negative mutants in chronic HBV infection. <i>Clinical Microbiology and Infection</i> , 1997, 3, 590-591. | 6.0 | 0 |
| 144 | Characterization and Biologic Activities of Recombinant Rat Soluble Interleukin-6 Receptor. <i>Journal of Interferon and Cytokine Research</i> , 1996, 16, 973-981. | 1.2 | 9 |